España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Glaukos
GKOS
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$140.83
-0.61
-0.43%
At close: -
$140.83
0
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Glaukos (GKOS) Forecast
News
Earnings
Glaukos (GKOS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Glaukos (NYSE:GKOS) Stock
Glaukos Stock (NYSE: GKOS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, November 05, 2024
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Vandana Singh
JP Morgan Maintains Overweight on Glaukos, Ra...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Monday, November 04, 2024
Glaukos shares are trading lower. The company...
Benzinga Newsdesk
Glaukos Sees 2024 Net Sales $377M-$379M
Benzinga Newsdesk
Glaukos Q3 2024 Adj. EPS $(0.28) Beats $(0.48...
Benzinga Newsdesk
Wednesday, October 30, 2024
How Is The Market Feeling About Glaukos?
Benzinga Insights
Wednesday, October 16, 2024
Glaukos Says Phase 3 Confirmatory Trial Of Ep...
Benzinga Newsdesk
Monday, October 14, 2024
A Closer Look at 7 Analyst Recommendations For Glaukos
Benzinga Insights
Truist Securities Maintains Buy on Glaukos, R...
Benzinga Newsdesk
Wednesday, September 11, 2024
Glaukos Stocks Rides on Strong Product Demand Amid Competition
Zacks
Tuesday, September 03, 2024
Stifel Maintains Buy on Glaukos, Raises Price...
Benzinga Newsdesk
Wednesday, August 28, 2024
Navigating 11 Analyst Ratings For Glaukos
Benzinga Insights
BTIG Maintains Buy on Glaukos, Raises Price T...
Benzinga Newsdesk
Thursday, August 01, 2024
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
Benzinga Insights
Glaukos Q2 Earnings In Line, Glaucoma Drives Sales
Zacks
Piper Sandler Maintains Overweight on Glaukos...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Truist Securities Reiterates Buy on Glaukos, ...
Benzinga Newsdesk
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
Needham Maintains Buy on Glaukos, Raises Pric...
Benzinga Newsdesk
Wednesday, July 31, 2024
Glaukos Sees FY24 Revenue $370M-$376M Vs $363...
Benzinga Newsdesk
Glaukos Q2 Adj $(0.52), Inline, Sales $95.69M...
Benzinga Newsdesk
Wednesday, July 17, 2024
Will WATCHMAN Sales Aid Boston Scientific's Q2 Earnings?
Zacks
Tuesday, July 16, 2024
Truist Securities Maintains Buy on Glaukos, R...
Benzinga Newsdesk
Monday, July 15, 2024
BTIG Maintains Buy on Glaukos, Raises Price T...
Benzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Glau...
Benzinga Newsdesk
Wednesday, July 10, 2024
10 Analysts Have This To Say About Glaukos
Benzinga Insights
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Avi Kapoor
Citigroup Downgrades Glaukos to Neutral, Rais...
Benzinga Newsdesk
Wednesday, July 03, 2024
Here's Why You Should Retain Glaukos Stock for Now
Zacks
Friday, June 14, 2024
Glaukos Corporation Reveals Agreements To Exc...
Benzinga Newsdesk
Wednesday, June 05, 2024
Stifel Maintains Buy on Glaukos, Raises Price...
Benzinga Newsdesk
Monday, June 03, 2024
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Wednesday, May 22, 2024
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
Benzinga Insights
Citigroup Maintains Buy on Glaukos, Raises Pr...
Benzinga Newsdesk
Monday, May 06, 2024
Jefferies Upgrades Glaukos to Buy, Raises Pri...
Benzinga Newsdesk
Thursday, May 02, 2024
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
Vandana Singh
BTIG Maintains Buy on Glaukos, Raises Price T...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Glaukos, Ra...
Benzinga Newsdesk
Glaukos shares are trading higher after the c...
Benzinga Newsdesk
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Wells Fargo Maintains Overweight on Glaukos, ...
Benzinga Newsdesk
Truist Securities Reiterates Buy on Glaukos, ...
Benzinga Newsdesk
Needham Maintains Buy on Glaukos, Raises Pric...
Benzinga Newsdesk
Wednesday, May 01, 2024
Glaukos Sees FY24 Net Sales $357M-$365M Vs $3...
Benzinga Newsdesk
Glaukos Q1 2024 Adj EPS $(0.70) Misses $(0.57...
Benzinga Newsdesk
Thursday, April 11, 2024
Mizuho Maintains Neutral on Glaukos, Raises P...
Benzinga Newsdesk
Monday, April 08, 2024
Analyst Ratings For Glaukos
Benzinga Insights
Truist Securities Reiterates Buy on Glaukos, ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch